GleamWall
中文EN

NDRA ENDRA Life Sciences Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1681682 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY27.0%
TTM EPS YoY-126.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-217.7%
ROA-134.7%
ROIC (approx.)-360.8%
Asset turnover—

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio7.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$176,280$233,665$776,410$508,137$432,113$381,061$528,685$637,957
SG&A expense$1.54M$1.24M$1.39M$1.11M$893,305$851,195$871,606$3.57M
Operating income-$1.72M-$1.48M-$2.17M-$1.62M-$1.37M-$1.30M-$1.47M-$4.30M
Pretax income-$1.53M$159,944-$1.31M-$3.17M-$1.60M-$1.23M-$1.04M-$4.15M
Income tax—————$0$0$0
Net income-$1.53M$159,944-$1.31M-$3.17M-$1.60M-$1.23M-$1.04M-$4.15M
EBITDA-$1.71M-$1.48M-$2.16M-$1.61M-$1.36M-$1.29M-$1.46M-$4.29M
EPS (basic)-1.020.12-1.09—-2.10-1.71-1.86—
EPS (diluted)-1.020.06-1.09—-2.10-1.71-1.86—
Weighted avg. shares (diluted)1.50M2.48M1.20M—761,218717,107557,582—
Balance sheet
Cash & equivalents$1.52M$1.74M$356,462$762,365$794,036$1.81M$2.06M$3.23M
Inventory———$0$0$0$0$0
Current assets$5.05M$5.59M$536,666$967,969$1.05M$1.85M$2.18M$3.43M
PP&E, net$35,603$43,538$33,024$42,516$52,633$63,419$63,419$69,281
Total assets$6.72M$7.94M$3.44M$3.85M$1.96M$2.81M$3.17M$4.45M
Current liabilities$635,724$786,578$835,440$750,956$800,307$576,637$565,785$605,230
Short-term debt———————$0
Long-term debt———————$0
Total debt———————$0
Total liabilities$1.52M$1.63M$1.65M$1.59M$1.79M$1.33M$1.42M$1.89M
Shareholders' equity$5.20M$6.31M$1.79M$2.26M$171,380$1.47M$1.75M$2.56M
Net debt———————-$3.23M
Shares outstanding1.50M1.50M1.24M1.18M786,902752,390562,213536,908
Cash flow statement
Operating cash flow-$1.75M-$927,560-$1.12M-$1.61M-$1.16M-$1.11M-$1.29M-$1.52M
Capital expenditure$0——$0$0$0$17,280$0
Free cash flow-$1.75M——-$1.61M-$1.16M-$1.11M-$1.31M-$1.52M
Investing cash flow$1.15M$2.22M$450,000-$3.00M$0$0-$17,280$0
Financing cash flow$0$3.89M$263,747$4.58M$149,466$857,415$145,803$0
Depreciation & amortization$7,935$8,156$9,492$10,117$10,786$9,356$13,786$11,000
Stock-based compensation$357,007$541,904$574,451$12,878$144,722$39,530$83,046$104,684

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.